Perjeta 420 mg (Pertuzumab) Solution

PERJETA 420 MG is a solution for intravenous use, containing pertuzumab. This medication is often used in combination with other treatments for specific types of cancer. It is manufactured by Hoffmann-La Roche Limited in Canada.

PERJETA 420 MG is primarily used in combination with other cancer treatments. It is designed to target certain proteins involved in cancer cell growth. This medication is often prescribed for specific types of breast cancer, particularly those that are HER2-positive. The exact use of PERJETA should be determined by a healthcare professional based on individual patient needs.

Common effects of PERJETA 420 MG may include infusion-related reactions such as fever, chills, and fatigue. Some patients may also experience nausea, diarrhea, or hair loss. These effects can vary from person to person and should be discussed with a healthcare provider.

PERJETA 420 MG should be handled with care and administered by a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions before starting treatment. Proper storage and handling instructions should be followed to ensure the medication remains effective.

PERJETA 420 MG may interact with other medications, including those that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain foods may also affect how this medication works, so it is best to follow specific dietary guidelines provided by a healthcare professional.